Printer Friendly

Hitachi, Redlen Technologies Team on Next Generation Medical Photon Counting CT System Development.

M2 PHARMA-March 7, 2016-Hitachi, Redlen Technologies Team on Next Generation Medical Photon Counting CT System Development

(C)2016 M2 COMMUNICATIONS

- Japanese electronics company Hitachi, Ltd.'s (TSX: 6501) Hitachi Medical Corp. subsidiary and Canadian technology company Redlen Technologies Inc. have agreed to jointly develop a direct conversion semiconductor x-ray detector module required for new photon counting computed tomography systems, the companies said on Monday.

The companies said that this is a promising next generation diagnostic medical imaging modality.

Hitachi has been focusing on the healthcare field as one of the Social Innovation Business, and has extensive expertise in healthcare total solutions which include medical diagnostic and clinical devices such as CT, MRI, particle beam therapy systems, and also informatics including medical service and platform.

Redlen is a manufacturer of high resolution Cadmium Zinc Telluride semiconductor radiation detectors which are used in the fields of medical imaging, security and nondestructive testing.

Under this agreement, Hitachi and Redlen will collaborate to develop a new multi-energy PCCT semiconductor detector module.

According to the companies, PCCT systems offer the potential for a breakthrough advance in CT diagnostic imaging performance through new capabilities which include material discrimination, higher image resolution, the addition of functional imaging and further radiation dose reduction.

Current commercial CT systems have limited to no knowledge of individual photon energies.

Redlen has developed semiconductor radiation sensors which have the ability to measure the unique energy of individual x-ray photons while operating at the very high count rates and stability levels necessary for x-ray computed tomography.

The additional information provided by these advanced radiation sensors is a key to realizing next generation PCCT advances.

Hitachi and Redlen will jointly develop the data acquisition technology required to process the order of magnitude higher amount of data received from these semiconductor radiation sensors and the packaging technology necessary for assembling the sensors into a detector module.

Exclusive use of the co-developed modules will enable Hitachi to develop an advanced PCCT which fully utilizes the performance of this new sensor technology.

Hitachi and Redlen said they will work closely to accelerate the joint development for the new detector modules. Hitachi will investigate a range of new diagnostic applications for PCCT based on the clinical evaluations planned both domestically and internationally.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2016 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Mar 7, 2016
Words:385
Previous Article:First Patients Enrolled in New Study to Expand Indication for NeoTract's UroLift System.
Next Article:Global Vein Illuminator Market to Reach USD 227.2m by 2022, MarketsandMarkets Predicts.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters